Caulerpin (CLP), an alkaloid from algae of the genus Caulerpa, has shown anti-inflammatory activity. Therefore, this study aimed to analyze the effect of CLP in the murine model of peritonitis and ulcerative colitis. Firstly, the mice were submitted to peritonitis to evaluate which dose of CLP (40, 4, or 0.4 mg/kg) could decrease the inflammatory infiltration in the peritoneum. The most effective doses were 40 and 4 mg/kg. Then, C57BL/6 mice were submitted to colitis development with 3% dextran sulfate sodium (DSS) and treated with CLP at doses of 40 and 4 mg/kg. The disease development was analyzed through the disease activity index (DAI); furthermore, colonic tissue samples were submitted to histological analysis, NFκB determination, and in vitro culture for cytokines assay. Therefore, CLP at 4 mg/kg presented the best results, triggering improvement of DAI and attenuating the colon shortening and damage. This dose was able to reduce the TNF-α, IFN-γ, IL-6, IL-17, and NFκB p65 levels, and increased the levels of IL-10 in the colon tissue. Thus, CLP mice treatment at a dose of 4 mg/kg showed promising results in ameliorating the damage observed in the ulcerative colitis.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6163434 | PMC |
http://dx.doi.org/10.3390/md16090318 | DOI Listing |
Ir J Med Sci
January 2025
Department of Urology, Başkent University Alanya Application and Research Center, Antalya, Türkiye.
Background: Inflammatory bowel disease (IBD) is a chronic disease that includes Crohn's disease and ulcerative colitis. Studies found that 40-60% of women diagnosed with IBD have sexual dysfunction (SD).
Aims: To determine SD and associated factors in women with IBD.
Naunyn Schmiedebergs Arch Pharmacol
January 2025
Department of Biological Sciences, National University of Medical Science, Rawalpindi, Punjab, Pakistan.
Cyclosporine A is an immunosuppressive drug used in clinics to treat steroid-refractory ulcerative colitis (UC). However, due to its side effects, researchers are evaluating novel drug delivery-based treatment options. Nanoparticles-based cyclosporine (Nano-CSA) offers a promising option for the treatment of UC, and various in vivo studies on animals have been conducted.
View Article and Find Full Text PDFImmun Inflamm Dis
January 2025
Department of Health Care, Qingdao Municipal Hospital, Qingdao, Shandong, China.
Purpose: C9orf72 deficiency contributes to severe inflammation in mice. Ulcerative colitis (UC) is a chronic inflammatory disorder with the shortage of clinical success. However, whether C9orf72 is involved in the progression of UC is not fully understood.
View Article and Find Full Text PDFRev Esp Enferm Dig
January 2025
Gastroenterology, Hospital Universitario Infanta Elena, Spain.
We present an interesting case of severe ulcerative colitis flare, of challenging management because of a cytomegalovirus co-infection, in which upadacitinib achieved clinical and biochemical remission after poor responses to ganciclovir and tofacitinib.
View Article and Find Full Text PDFFront Cell Dev Biol
January 2025
Division of Gastroenterology and Hepatology, Department of Medicine, Penn State College of Medicine, Hershey, PA, United States.
Telocytes, a novel mesenchymal cell population, are characterized by their distinctive long and slender projections known as telopodes and have garnered significant interest since their formal introduction to the literature in 2010. These cells have been identified in various tissues, including the gastrointestinal (GI) tract, where they are suggested to play important roles in maintaining structural integrity, immune modulation, and barrier function. Inflammatory bowel diseases (IBD), which include Crohn's disease (CD) and ulcerative colitis (UC), are characterized by chronic inflammation and fibrosis.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!